Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028969 | 0.78 | MAPT (0.44) | MAPTNPSR1PRKDCACHEPOLB | |
| SCHEMBL14581179 | 0.78 | MAPT (0.44) | MAPTNPSR1PRKDCACHEPOLB | |
| SCHEMBL28844605 | 0.77 | MAPT (0.43) | MAPTNPSR1POLBL3MBTL1HTR2A | |
| SCHEMBL14811235 | 0.76 | HTR2A (0.47) | MAPTNPSR1HTR2ATAAR1 | |
| SCHEMBL31081199 | 0.75 | CYP1A2 (0.43) | MAPTNPSR1ACHELCKFYN | |
| SCHEMBL661281 | 0.75 | CYP1A2 (0.43) | MAPTNPSR1ACHELCKFYN | |
| SCHEMBL31081166 | 0.74 | LCK (0.59) | MAPTNPSR1PRKDCACHELCK | |
| SCHEMBL660822 | 0.74 | PRKDC (0.77) | MAPTNPSR1PRKDCACHEPOLB | |
| SCHEMBL5355957 | 0.74 | PDE4A (0.46) | MAPTNPSR1HTR2ATAAR1 | |
| SCHEMBL5354491 | 0.74 | HTR2A (0.45) | MAPTNPSR1HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363880-A4 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | UNIV AUSTRALIAN (AU) | 2008-10-08 | — | — | EP | disclosed |
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2005-06-16 | — | — | US | disclosed |
| EP-1363880-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002060872-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | TUBB, TUBB3, TUBB1 | MAPT 28/4885NPSR1 3662/4885PRKDC 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.